Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03287232 · ClinicalTrials.gov registry record · Phase 3
Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD)
A Phase 3 study of Hypoactive Sexual Desire Disorder, sponsored by EndoCeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 653
- Enrollment target
- 20
- Study locations
NCT03287232 is a Phase 3 study of Hypoactive Sexual Desire Disorder that has completed, run by EndoCeutics. The registered enrollment target is 653 participants, above the 322-participant average among 8 other Hypoactive Sexual Desire Disorder trials with a reported enrollment target (103% higher). The trial reports 20 study locations across 7 states.
The verdict
NCT03287232, a Phase 3 study of Hypoactive Sexual Desire Disorder, has completed, sponsored by EndoCeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 653 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective is to confirm the efficacy of intravaginal prasterone (DHEA) on Hypoactive Sexual Desire Disorder (HSDD) in postmenopausal women.
Conditions Studied
Interventions
- DRUG Placebo Vaginal Insert
- DRUG Prasterone 6.5 mg (0.50%) Vaginal Insert
Study Locations (20)
Florida
- Endoceutics site # 95 - Bradenton
- Endoceutics site # 120 - Coral Gables
- Endoceutics site # 99 - Fort Myers
- Endoceutics site # 26 - Jacksonville
- Endoceutics site # 60 - Lake Worth
- Endoceutics site #118 - Miami Lakes
- Endoceutics site # 54 - North Miami
- Endoceutics site # 92 - Oviedo
California
- Endoceutics site # 108 - Berkeley
- Endoceutics site # 121 - Los Alamitos
- Endoceutics site #128 - Los Angeles
- Endoceutics site # 30 - San Diego
- Endoceutics site # 17 - San Diego
Alabama
- Endoceutics site # 106 - Huntsville
- Endoceutics site # 104 - Mobile
Colorado
- Endoceutics site # 36 - Denver
- Endoceutics site # 52 - Denver
Arizona
- Endoceutics site # 117 - Tucson
Connecticut
- Endoceutics site # 125 - New London
District of Columbia
- Endoceutics site # 7 - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 653 participants |
| Start Date | 2017-10-16 |
| Est. Completion | 2019-07-22 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03287232
The ClinicalTrials.gov registry entry for NCT03287232 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 653 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 322-participant average among 8 other Hypoactive Sexual Desire Disorder trials with a reported enrollment target (103% higher). The listed sponsor is EndoCeutics, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hypoactive Sexual Desire Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo Vaginal Insert is the first listed.
NCT03287232 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Florida, California, Alabama.
Frequently Asked Questions
What is clinical trial NCT03287232 about?
NCT03287232 is a clinical study titled "Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD)". The primary objective is to confirm the efficacy of intravaginal prasterone (DHEA) on Hypoactive Sexual Desire Disorder (HSDD) in postmenopausal women.
What is the current status of trial NCT03287232?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 653 participants. The study started on 2017-10-16. Estimated completion is 2019-07-22.
What conditions does trial NCT03287232 study?
This clinical trial studies the following conditions: Hypoactive Sexual Desire Disorder.
What interventions are being tested in trial NCT03287232?
The interventions under investigation include: Placebo Vaginal Insert (DRUG), Prasterone 6.5 mg (0.50%) Vaginal Insert (DRUG).
Who is sponsoring clinical trial NCT03287232?
This trial is sponsored by EndoCeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03287232 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypoactive Sexual Desire Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety and Efficacy of LibiGel® for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women
COMPLETED · Phase 3
-
2. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder
COMPLETED · Phase 3
-
Safety and Efficacy of LibiGel® for Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women
COMPLETED · Phase 3
-
Lybridos in Pre-and Postmenopausal Women With Hypoactive Sexual Desire Disorder
COMPLETED · Phase 2
-
A Mindfulness-based Intervention for Older Women With Low Sexual Desire
COMPLETED · NA
-
Lybridos in Pre- and Postmenopausal Women With Hypoactive Sexual Desire Disorder Due to Maladaptive Activation of Sexual Inhibitory Systems
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.